Navigation Links
Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
Date:12/10/2008

therapy aimed at inducing a remission; some patients may go on to receive a hematopoietic stem cell transplant. Although cure rates have been reported to be 20-45%, this is likely to be much lower for elderly patients and those who cannot tolerate aggressive therapy.

About CLL

CLL(chronic lymphocytic leukemia) is a cancer of the lymphocytic line of white blood cells. CLL affects a particular lymphocyte, the B cell, which originates in the bone marrow, develops in the lymph nodes, and normally fights infection. In CLL, the DNA of a B cell is damaged, so that it can't fight infection, but it grows out of control and crowds out the healthy blood cells that can fight infection. While generally considered incurable, CLL progresses slowly in most cases. Determining when to start treatment and by what means is often difficult. In addition, several drugs are used to treat CLL, however Fludarabine is the most extensively studied and is currently the most commonly used first-line therapy in this disease.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast trac
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
2. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
5. Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers
6. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
7. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
8. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
9. Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a Clinical ... relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO seeks ... and regulatory pathways., , Stem Cell Meeting on the ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech ... R&D capability and technology platform company serving the pharmaceutical, ... Ltd. ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), ... Kong with 20 years of operations in ... two companies have signed an agreement whereby WuXi,s Laboratory ...
Breaking Biology Technology:Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... at, http://www.StopAfib.org, announces that September is Atrial Fibrillation,Month ... afib or AF., Once considered benign, this common ... stroke. Every five minutes, someone in the,U.S. has a ... and the #1 cause of,permanent disability, and takes a ...
... ... 2 -, BRISBANE, Calif., Sept. 2 InterMune, Inc.,(Nasdaq: ... $15 million,development milestone under its development collaboration with Roche for,the ... as R7227 at Roche), currently in a Phase 1b clinical ...
... SAN MATEO, Calif., Sept. 2 NeurogesX, Inc.,(Nasdaq: ... developing and,commercializing novel pain management therapies, announced today ... scheduled to,present at the Morgan Stanley Global Healthcare ... 9, 2008. Mr. DiTonno and Stephen Ghiglieri,Chief Financial ...
Cached Biology Technology:Atrial Fibrillation Month - StopAfib.org Announces September Focus on Life-Threatening Irregular Heartbeat 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3
(Date:8/6/2015)... and TELTOW, Germany , ... 2015 Siggraph Conference, SensoMotoric Instruments (SMI) shows ... reality , based on Epson,s Moverio BT-200 ... tracking platform. With this new solution, unprecedented quality and ... hands-free interaction with context-sensitive displays. For the first time, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... traditional French and Lady Gaga,s sophisticated designs, manicured nails have ... just pretty when nails appeared on all fingers and ... led to the development of critical functions, including finger pads ... whether it,s a nail polish brush or remover to prepare ...
... of mammary gland biology are essential in the fight ... as an Experimental Model , this organ represents an ... processes that occur throughout the body. The branching morphogenesis ... pregnancy, for example, recapitulate steps that occur in many ...
... roads as weed highways, and chemical warfare between alien and native ... in NeoBiota a new open-access, peer-reviewed, rapid ... Pensoft Publishers continuing the former NeoBiota Proceedings ... Khn from the Helmholtz Centre for Environmental Research ...
Cached Biology News:Researchers discover oldest evidence of nails in modern primates 2Researchers discover oldest evidence of nails in modern primates 3Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 3